Abstract
Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization
Current Clinical Pharmacology
Title: Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives
Volume: 5 Issue: 3
Author(s): Otto Metzger-Filho, Camilo Moulin and Ahmad Awada
Affiliation:
Keywords: Targeted therapy, breast cancer, lung cancer, colorectal cancer, resistance, therapy individualization
Abstract: Important advances have been achieved with molecular targeted agents in clinical oncology. Breast, colon, and lung cancer, are now commonly treated with a combination of chemotherapy and targeted agents. In this article the authors discuss the limitations of targeted therapy development, failures of previous studies, and possible strategies for an intelligent drug development. Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on K-RAS status are discussed.
Export Options
About this article
Cite this article as:
Metzger-Filho Otto, Moulin Camilo and Awada Ahmad, Molecular Targeted Therapy in Prevalent Tumors: Learning from the Past and Future Perspectives, Current Clinical Pharmacology 2010; 5 (3) . https://dx.doi.org/10.2174/157488410791498716
DOI https://dx.doi.org/10.2174/157488410791498716 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment
Current Cancer Therapy Reviews Preclinical Toxicity of Paclitaxel Biopolymer Formulation
Anti-Cancer Agents in Medicinal Chemistry The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Imino-Sugar-Based Nucleosides
Current Topics in Medicinal Chemistry Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Radioactive Gold Nanoparticle in Two Forms (<sup>198</sup><sub>79</sub>Au GNPs and <sup>99m</sup>Tc-GNPs) for Lung Cancer Antiproliferative Induction and Intralesional Imaging: A Proof of Concept
Anti-Cancer Agents in Medicinal Chemistry Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Recent Progress in Quantitative Proteomics Using Stable Isotope Labeling, Multidimensional Liquid Chromatography and Mass Spectrometry
Current Proteomics Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers
Current Drug Targets Patent Review
Combinatorial Chemistry & High Throughput Screening Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients
Current Cancer Drug Targets DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Metabolic Effects of Bile Acids in the Gut in Health and Disease
Current Medicinal Chemistry Synthesis and Molecular Docking of New Thiophene Derivatives as Lactate Dehydrogenase-A Inhibitors
Mini-Reviews in Medicinal Chemistry